Dr. Jason Lewis has recently been appointed as the inaugural Director of Memorial Sloan Kettering’s Center for Molecular Imaging and Nanotechnology (CMINT). The central mission of CMINT will be to develop novel molecular imaging methods and nanotechnology methods that will accelerate the understanding of human cancer biology. Gaining further traction in imaging and assessing patients’ cancers will undoubtedly aid in the design of curative cancer therapeutic regimens as well as cutting-edge diagnostic, prognostic, and therapeutic tools. The CMINT research portfolio is situated at the intersection of various disciplines — cancer biology, developmental biology, nanotechnology, medicine, chemistry, physics, radiochemistry, genomics, pharmacology and engineering – from cells to human translation – and as such spans faculty from every corner of MSKCC.

Jason holds the Emily Tow Jackson Chair in Oncology and is the Vice Chair of Research in Radiology with a joint appointment in the Molecular Pharmacology and Chemistry Program. His molecular imaging-based research program is focused on radiopharmaceutical development as well as the study of multimodality (PET, CT & MRI) small- and biomolecule-based agents and their clinical translation.

Originally posted on Memorial Sloan Kettering Cancer Center website

Learn more @ Memorial Sloan Kettering